



Conclusions



3.A.2.4. Summary of SnF₂ Antiplaque Results

Multiple studies identified in the literature and carried out by Procter & Gamble provide additional support that 0.454% stannous fluoride dentifrices provide meaningful clinical plaque mass reductions. P&G studies provided herein include a standard 6-month gingivitis clinical trial on an improved dentifrice, a 21-day experimental gingivitis (EG) study and multiple Digital Plaque Imaging Assays (DPIA) studies on stannous fluoride dentifrice formulations. These data demonstrate that consistent plaque mass reductions can be measured for SnF₂. Furthermore, in all of these studies the plaque reduction was statistically significant with corresponding gingivitis reductions exceeding 20%.

Stannous Fluoride Performance Summary (% reduction)

	Northeast 6-month Trial	Southeast 6-month Trial	Unpublished 6-month Trial	21-Day Exp. Gingivitis	DPIA
Gingivitis	21.0% p<0.0001	22.3% p<0.001	21.7% p<0.001	22% p<0.0001	na*
Plaque	20.3% p<0.0001	22.7% p<0.001	6.9% p<0.014	19% p<0.0001	12-35% p<0.05

* Not applicable